Evaluation of potential drug–drug interactions with medical cannabis

Ähnliche Einträge

• Predictors of potential clinically harmful drug–drug interactions at the medical wards in the University of Benin Teaching Hospital, Benin City
  von: Oseremen Godstime Oriaifo, et al.
  Veröffentlicht: (2024)
• Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
  von: Jingcheng Chen, et al.
  Veröffentlicht: (2024)
• Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population
  von: Simon Dagenais, et al.
  Veröffentlicht: (2024)
• No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
  von: Wonsuk Shin, et al.
  Veröffentlicht: (2024)
• A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
  von: Amanda Long, et al.
  Veröffentlicht: (2024)